International prognostic scoring system for Waldenstrom macroglobulinemia

  • Morel P
  • Duhamel A
  • Gobbi P
 et al. 
  • 5

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Recently, many new drugs have been developed for the treatment of Waldenstrom macroglobulinemia (WM). To optimize the treatment according to the prognosis and to facilitate the comparison of trials, we developed an International Prognostic Scoring System for WM in a series of 587 patients with clearly defined criteria for diagnosis and for initiation of treatment. The median survival after treatment initiation was 87 months. Five adverse covariates were identified: advanced age (>65 years), hemoglobin less than or equal to 11.5 g/dL, platelet count less than or equal to 100 x 10(9)/L, beta2-microglobulin more than 3 mg/L, and serum monoclonal protein concentration more than 7.0 g/dL. Low-risk patients (27%) presented with no or 1 of the adverse characteristics and advanced age, intermediate-risk patients (38%) with 2 adverse characteristics or only advanced age, and high-risk patients (35%) with more than 2 adverse characteristics. Five-year survival rates were 87%, 68%, and 36%, respectively (P < .001). The ISSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and purine analog. Thus, the ISSWM may provide a means to design risk-adapted studies. However, independent validation and new biologic markers may enhance its significance.

Author-supplied keywords

  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/ th
  • Female
  • Humans
  • International Classification of Diseases
  • Male
  • Prognosis
  • Survival Rate
  • Treatment Outcome
  • Validation Studies as Topic
  • Waldenstrom Macroglobulinemia/ classification/ dia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • P Morel

  • A Duhamel

  • P Gobbi

  • M A Dimopoulos

  • M V Dhodapkar

  • J McCoy

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free